{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:50:30Z","timestamp":1789105830128,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    Response to treatment in multiple myeloma (MM) is routinely measured by serum and urine M-protein and free light chain (FLC), as described by the International Myeloma Working Group (IMWG) consensus statement. A non-negligible subgroup of patients however present without measurable biomarkers, others become oligo or non-secretory during recurrent relapses. The aim of our research was to evaluate soluble B-cell maturation antigen (sBCMA) as a monitoring marker measured concurrent with the standard monitoring in MM patients at diagnosis, at relapse and during follow up, in order to establish its potential usefulness in oligo and non-secretory disease.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Method:<\/jats:bold>\n                    sBCMA levels were measured in 149 patients treated for plasma cell dyscrasia (3 monoclonal gammopathy of unknown significance, 5 smoldering myeloma, 7 plasmacytoma, 8 AL amyloidosis and 126\u00a0MM) and 16 control subjects using a commercial ELISA kit. In 43 newly diagnosed patients sBCMA levels were measured at multiple timepoints during treatment, and compared to conventional IMWG response and progression free survival (PFS).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    sBCMA levels among control subjects were significantly lower than among newly diagnosed or relapsed MM patients [20.8 (14.7\u201338.7) ng\/mL vs. 676 (89.5\u20131,650) and 264 (20.7\u20131,603) ng\/mL, respectively]. Significant correlations were found between sBCMA and the degree of bone marrow plasma cell infiltration. Out of the 37 newly diagnosed patients who have reached partial response or better per IMWG criteria, 33 (89%) have had at least a 50% drop in sBCMA level by therapy week 4. Cohorts made similarly to IMWG response criteria\u2014achieving a 50% or 90% drop in sBCMA levels compared to level at diagnosis\u2014had statistically significant differences in PFS.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Our results confirmed that sBCMA levels are prognostic at important decision points in myeloma, and the percentage of BCMA change is predictive for PFS. This highlights the great potential use of sBCMA in oligo- and non-secretory myeloma.\n                  <\/jats:p>","DOI":"10.3389\/pore.2023.1611171","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T10:37:41Z","timestamp":1682678261000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma"],"prefix":"10.3389","volume":"29","author":[{"given":"\u00c1d\u00e1m","family":"Wiedemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vir\u00e1g R\u00e9ka","family":"Szita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00f3bert","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Szederjesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Seb\u0151","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s D\u00e1vid","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0889-8588(05)70125-8","article-title":"Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia","volume":"13","author":"Blade","year":"1999","journal-title":"Hematol\/oncol Clin North Am"},{"key":"B4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/hon.2900040407","article-title":"Non-secretory multiple myeloma: A report of 13 cases with a review of the literature","volume":"4","author":"Smith","year":"1986","journal-title":"Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2141.2007.06691.x","article-title":"Non-secretory plasma cell myeloma of the true non-producer type","volume":"138","author":"Ma","year":"2007","journal-title":"Br J Haematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1189\/jlb.0803382","article-title":"Immunologic basis for the rare occurrence of true nonsecretory plasma cell dyscrasias","volume":"76","author":"Decourt","year":"2004","journal-title":"J Leukoc Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1182\/blood-2004-02-0477","article-title":"A molecular basis for nonsecretory myeloma","volume":"104","author":"Coriu","year":"2004","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): A dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.3390\/cimb44040098","article-title":"sBCMA plasma level dynamics and anti-BCMA CAR-T-cell treatment in relapsed multiple myeloma","volume":"44","author":"Seipel","year":"2022","journal-title":"Curr Issues Mol Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41408-021-00505-4","article-title":"Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: A novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1182\/blood.V124.21.3405.3405","article-title":"Serum B-cell maturation antigen is a novel prognostic indicator for multiple myeloma patients and correlates with clinical status and survival","volume":"124","author":"Ghermezi","year":"2014","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1182\/bloodadvances.2021006762","article-title":"Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma","volume":"6","author":"Puig","year":"2022","journal-title":"Blood Adv"},{"key":"B21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.mayocp.2021.07.024","article-title":"Detection of plasma cell disorders by mass spectrometry: A comprehensive review of 19,523 cases","volume":"97","author":"Dasari","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"B22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41408-020-0291-8","article-title":"Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis","volume":"10","author":"Dispenzieri","year":"2020","journal-title":"Blood Cancer J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.bbmt.2012.03.004","article-title":"Prognostic impact of serum immunoglobulin heavy\/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation","volume":"18","author":"Tovar","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1182\/blood.v95.2.388","article-title":"Serum syndecan-1: A new independent prognostic marker in multiple myeloma","volume":"95","author":"Seidel","year":"2000","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/j.1365-2141.2005.05647.x","article-title":"Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival","volume":"130","author":"Richard","year":"2005","journal-title":"B J Haem"},{"key":"B27","first-page":"370","article-title":"Soluble syndecan-1 levels in different plasma cell dyscrasias and in different stages of multiple myeloma","volume":"89","author":"Janosi","year":"2004","journal-title":"Haematologica"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2023.1611171\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T10:37:43Z","timestamp":1682678263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2023.1611171\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":27,"alternative-id":["10.3389\/pore.2023.1611171"],"URL":"https:\/\/doi.org\/10.3389\/pore.2023.1611171","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"article-number":"1611171"}}